Patients with luminal A (ER+/PR+/HER2-) and luminal HER2+ breast cancer had a 1.5% and 1.0% risk for local recurrence at a median follow-up of 85 and 82 months, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.